Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma

Laboratory Investigation

Volumn 88, Issue 5, 2008, Pages 474-481

  Ferrario, Cristina ^a,b   Lavagni, Paola ^a   Gariboldi, Manuela ^a,b   Miranda, Claudia ^a   Losa, Marco ^a   Cleris, Loredana ^a   Formelli, Franca ^a   Pilotti, Silvana ^a   Pierotti, Marco A ^a,b   Greco, Angela ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Gene expression; K1 cell line; Metallothionein; Papillary thyroid carcinoma; Thyroid carcinogenesis

Indexed keywords

ISOPROTEIN; METALLOTHIONEIN 1G; METALLOTHIONEIN I; METALLOTHIONEIN II; MYC PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METHYLATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID TUMOR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

CARCINOMA; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; DNA METHYLATION; DNA, COMPLEMENTARY; DOWN-REGULATION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; METALLOTHIONEIN; MICROARRAY ANALYSIS; PROMOTER REGIONS (GENETICS); THYROID NEOPLASMS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 42549171532     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.17     Document Type: Article

References (33)

1. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-511.
2. Pierotti MA, Bongarzone I, Borrello MG, et al. Cytogenetics and molecular genetics of the carcinomas arising from the thyroid epithelial follicular cells. Genes Chromosome Cancer 1996;16:1-14.
3. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-4567.
4. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: gene evidence for constitutive activation of RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457.
5. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23:7436-7440.
6. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 2001;98:15044-15049.
7. Barden CB, Shister KW, Zhu B, et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 2003;9:1792-1800.
8. Aldred MA, Huang Y, Liyanarachchi S, et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 2004;22:3531-3539.
9. Jarzab B, Wiench M, Fujarewicz K, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 2005;65:1587-1597.
10. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005;24:6646-6656.
11. Fischer EH, Davie EW. Recent excitement regarding metallothionein. Proc Natl Acad Sci USA 1998;95:3333-3334.
12. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003;533:201-209.
13. Hunziker PE. Purification of human isometallothioneins. Methods Enzymol 1991;205:244-247.
14. Haq F, Mahoney M, Koropatnick J. Signaling events for metallothionein induction. Mutat Res 2003;533:211-226.
15. Theocharis SE, Margeli AP, Klijanienko JT, et al. Metallothionein expression in human neoplasia. Histopathology 2004;45:103-118.
16. Weinlich G, Bitterlich W, Mayr V, et al. Metallothionein- overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients. Br J Dermatol 2003;149:535-541.
17. Joseph MG, Banerjee D, Kocha W, et al. Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer 2001;92:836-842.
18. Chun JH, Kim HK, Kim E, et al. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res 2004;64:4703-4706.
19. Deng DX, Chakrabarti S, Waalkes MP, et al. Metallothionein and apoptosis in primary human hepatocellular carcinoma and metastatic adenocarcinoma. Histopathology 1998;32:340-347.
20. Stenram U, Ohlsson B, Tranberg KG. Immunohistochemical expression of metallothionein in resected hepatic primary tumors and colorectal carcinoma metastases. APMIS 1999;107:420-424.
21. Datta J, Majumder S, Kutay H, et al. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 2007;67:2736-2746.
22. Huang Y, de la Chapelle A, Pellegata NS. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 2003;104:735-744.
23. Schmid KW, Greeff M, Hittmair A, et al. Metallothionein expression in normal, hyperplastic, and neoplastic thyroid follicular and parafollicular C cells using monoclonal antimetallothionein antibody E9. Endocrinol Pathol 1994;5:114-122.
24. De Cecco L, Marchionni L, Gariboldi M, et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 2004;23:8171-8183.
25. Mididoddi S, McGuirt JP, Sens MA, et al. Isoform-specific expression of metallothionein mRNA in the developing and adult human kidney. Toxicol Lett 1996;85:17-27.
26. Nicassio F, Bianchi F, Capra M, et al. A cancer-specific transcriptional signature in human neoplasia. J Clin Invest 2005;115:3015-3025.
27. Tai SK, Tan OJ, Chow VT, et al. Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. Am J Pathol 2003;163:2009-2019.
28. Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003;9:827-836.
29. Detre S, Saclani JG, Dowsett M. A 'quickscore' method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-878.
30. UK Committee on Cancer Research. UKCCCR guide lines for the welfare of animals in experimental neoplasia. Br J Cancer 1988;58:109-113.
31. Nartey N, Cherian MG, Banerjee D. Immunohistochemical localization of metallothionein in human thyroid tumors. Am J Pathol 1987;129:177-182.
32. Finn SP, Smyth P, Chill S, et al. Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Arch 2007;450:249-260.
33. Liu D, Liu Z, Condouris S, et al. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. Clin Endocrinol Metab 2007;92:2264-2271.